Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 0.83 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.83 |
| ▸ | LMNA | P02545 | 3/20 | 0.75 |
| ▸ | NPC1 | O15118 | 11/20 | 0.71 |
| ▸ | RAB9A | P51151 | 11/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.71 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | PNLIP | P16233 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.61 |
| ▸ | RELA | Q04206 | 1/20 | 0.61 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.61 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6811714 | 0.92 | KMT2A (0.71) | KMT2AMEN1TDP1LMNANPC1 | |
| SCHEMBL6295702 | 0.86 | LMNA (1.00) | KMT2AMEN1TDP1LMNANPC1 | |
| SCHEMBL30739608 | 0.86 | LMNA (1.00) | KMT2AMEN1TDP1LMNANPC1 | |
| SCHEMBL4363732 | 0.85 | MEN1 (0.89) | KMT2AMEN1TDP1LMNANPC1 | |
| SCHEMBL6811720 | 0.85 | KMT2A (0.60) | KMT2AMEN1TDP1LMNANPC1 | |
| Dimethylamine SCHEMBL9686168 | 0.84 | NPC1 (0.65) | KMT2AMEN1TDP1LMNANPC1 | |
| SCHEMBL3286361 | 0.83 | MEN1 (0.77) | KMT2AMEN1TDP1LMNANPC1 | |
| SCHEMBL4825016 | 0.83 | KMT2A (0.83) | KMT2AMEN1TDP1LMNANPC1 | |
| SCHEMBL679040 | 0.83 | MEN1 (0.83) | KMT2AMEN1TDP1LMNANPC1 | |
| SCHEMBL17115776 | 0.83 | NPC1 (1.00) | KMT2AMEN1TDP1LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120058540-A | Method for preparing halogenated 2-aminobenzophenone by continuous photochemical rearrangement | 姚昕辰 | 2025-05-30 | — | — | CN | claimed |
| CN-120058540-A | Method for preparing halogenated 2-aminobenzophenone by continuous photochemical rearrangement | 姚昕辰 | 2025-05-30 | — | — | CN | disclosed |
| CN-114853582-A | Method for preparing aryl ketone through green continuous photochemical rearrangement | 姚昕辰 | 2022-08-05 | — | — | CN | disclosed |
| US-6897316-B2 | Substituted 2-phenyl-4-quinolone-3-carboxylic acid compounds and their use as antitumor agents | CHINA MEDICAL UNIVERSITY (TW) | 2005-05-24 | — | — | US | disclosed |
| US-20050032832-A1 | Substituted 2-phenyl-4-quinolone-3-carboxylic acid compounds and their use as antitumor agents | CHINA MEDICAL UNIVERSITY (TW) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032832-A1 | Substituted 2-phenyl-4-quinolone-3-carboxylic acid compounds and their use as antitumor agents | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHUK | KMT2A 780/4885MEN1 3877/4885TDP1 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.